Earlier this month, ' (NYSE: NVS) smash-hit immunology medicine Cosentyx became the first drug within its class to be approved in the European Union to treat adult patients with moderate to severe hidradenitis suppurativa (HS).

What was the reasoning for the European Commission's approval of Cosentyx's sixth indication? And how much of a boost could it provide to Novartis' sales? Let's explore Cosentyx's phase 3 clinical trial results and the European HS market to try to arrive at some answers. 

HS is a lifelong, progressive, inflammatory skin condition that can cause great discomfort to patients. The disease results in repeated abscesses that can burst, which creates open wounds, most often around the armpits and groin. This can lead to symptoms such as burning, itching, or sweating sensations around the skin, scarring, and slowly healing skin.

Continue reading

Source Fool.com